We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Valeant Pharmaceuticals Agrees to Acquire Amoun Pharmaceutical
News

Valeant Pharmaceuticals Agrees to Acquire Amoun Pharmaceutical

Valeant Pharmaceuticals Agrees to Acquire Amoun Pharmaceutical
News

Valeant Pharmaceuticals Agrees to Acquire Amoun Pharmaceutical

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Valeant Pharmaceuticals Agrees to Acquire Amoun Pharmaceutical"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Valeant Pharmaceuticals International, Inc. has announced that it has entered into a definitive agreement under which Valeant will acquire Mercury (Cayman) Holdings, the holding company of Amoun Pharmaceutical, for consideration of approximately US$800 million, plus contingent payments.

Amoun Pharmaceutical is the largest domestic company in the Egyptian pharmaceutical market and currently expects to reach EGP 1.75 billion by 2015, with annual growth of approximately 20%.

Amoun operates a large, manufacturing plant that is considered to be one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East and has market leading pharmaceutical brands in therapeutic areas such as anti-hypertensives, broad spectrum antibiotics and anti-diarrheals.

Valeant intends for Amoun to serve as a platform for further expansion in the broader Middle East and North Africa pharmaceutical market and expects the transaction to close in the third quarter, subject to customary closing conditions.

Advertisement